Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to ...
Karuna Therapeutics Inc (NASDAQ: KRTX) and Goldfinch Bio entered into an exclusive license agreement under which Karuna will obtain global rights to Goldfinch Bio's investigational transient receptor ...
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and China Pharmaceutical University presented the discovery of novel orally bioavailable inhibitors of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences, Inc. (Hydra), a global leader in Transient Receptor Potential (TRP) channel modulation announced today that Boehringer Ingelheim has initiated a ...
Karuna Therapeutics, Inc. KRTX announced a definitive agreement with Goldfinch Bio assignment estate to acquire global development, manufacturing and commercialization rights to the latter's transient ...
Karuna Therapeutics, Inc. (NASDAQ: KRTX) and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results